依帕珠单抗治疗系统性红斑狼疮。
Treatment of systemic lupus erythematosus with epratuzumab.
机构信息
Dept. Dermatology CSK MSWiA, Warsaw, Poland.
出版信息
Br J Clin Pharmacol. 2011 Feb;71(2):175-82. doi: 10.1111/j.1365-2125.2010.03767.x.
Abstract
Systemic lupus erythematosus is a prototypic autoimmune disease characterized by abnormalities in the activity of B-cells and T-cells. A novel specific treatment for autoimmune diseases is B-cell depletion with monoclonal antibodies. Epratuzumab is a monoclonal antibody that targets CD22 antigen on B-cells. Initial phase II and two terminated early phase III studies suggest that treatment of systemic lupus erythematosus with this immunomodulatory agent is effective, well tolerated and significantly improves the patient's quality of life. In vitro studies and clinical trials with non-Hodgkin lymphoma patients indicate epratuzumab can potentially serve as a complementary drug in combination therapy with another inhibitor of B-cell activity, rituximab, which is a monoclonal anti-CD20 antibody.
摘要
系统性红斑狼疮是一种典型的自身免疫性疾病，其特征是 B 细胞和 T 细胞活性异常。B 细胞耗竭单克隆抗体是一种治疗自身免疫性疾病的新方法。依帕珠单抗是一种针对 B 细胞 CD22 抗原的单克隆抗体。初步的 II 期和两项提前终止的 III 期研究表明，用这种免疫调节剂治疗系统性红斑狼疮是有效且耐受性良好的，并且可以显著改善患者的生活质量。非霍奇金淋巴瘤患者的体外研究和临床试验表明，依帕珠单抗可能可作为与另一种 B 细胞活性抑制剂利妥昔单抗联合治疗的辅助药物，利妥昔单抗是一种抗 CD20 的单克隆抗体。
相似文献
1
Treatment of systemic lupus erythematosus with epratuzumab.依帕珠单抗治疗系统性红斑狼疮。
Br J Clin Pharmacol. 2011 Feb;71(2):175-82. doi: 10.1111/j.1365-2125.2010.03767.x.
2
B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.B 细胞靶向治疗系统性红斑狼疮：成就与挑战。
BioDrugs. 2013 Apr;27(2):85-95. doi: 10.1007/s40259-013-0015-8.
3
Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.依帕珠单抗（人源化抗CD22抗体）在自身免疫性疾病中的应用。
Expert Opin Biol Ther. 2006 Sep;6(9):943-9. doi: 10.1517/14712598.6.9.943.
4
Epratuzumab for systemic lupus erythematosus.依帕珠单抗治疗系统性红斑狼疮。
Lupus. 2013 Apr;22(4):400-5. doi: 10.1177/0961203312469692.
5
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.具有增强的穿胞作用用于治疗狼疮的抗CD22/CD20双特异性抗体。
PLoS One. 2014 May 19;9(5):e98315. doi: 10.1371/journal.pone.0098315. eCollection 2014.
6
Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again.系统性红斑狼疮中针对B细胞：并非只是似曾相识。
Arthritis Res Ther. 2006;8(3):108. doi: 10.1186/ar1967. Epub 2006 May 15.
7
B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.使用抗CD22单克隆抗体依帕珠单抗进行B细胞治疗：对圣克莱尔和特德编辑文章的评论
Arthritis Rheum. 2006 Jul;54(7):2344; author reply 2344-5. doi: 10.1002/art.21937.
8
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.依帕珠单抗与 CD22 结合对 B 细胞功能的作用机制：对系统性红斑狼疮治疗的影响。
Autoimmun Rev. 2015 Dec;14(12):1079-86. doi: 10.1016/j.autrev.2015.07.013. Epub 2015 Jul 23.
9
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.依帕珠单抗（人源化抗CD22抗体）用于系统性红斑狼疮免疫治疗的初步临床试验。
Arthritis Res Ther. 2006;8(3):R74. doi: 10.1186/ar1942. Epub 2006 Apr 21.
10
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.依帕珠单抗，一种抗 CD22 单克隆 IgG 抗体，在伴有干燥综合征的系统性红斑狼疮患者中的疗效：来自 EMBODY 试验的事后分析。
Arthritis Rheumatol. 2018 May;70(5):763-773. doi: 10.1002/art.40425. Epub 2018 Apr 12.
引用本文的文献
1
Systemic lupus erythematosus: pathogenesis and targeted therapy.系统性红斑狼疮：发病机制与靶向治疗。
Mol Biomed. 2024 Oct 30;5(1):54. doi: 10.1186/s43556-024-00217-8.
2
Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.单剂量他巴鲁单抗在类风湿性关节炎或系统性红斑狼疮患者中的药代动力学及安全性
Br J Clin Pharmacol. 2016 May;81(5):908-17. doi: 10.1111/bcp.12860. Epub 2016 Feb 25.
3
Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.依帕珠单抗简介及其在系统性红斑狼疮治疗中的潜力。
Drug Des Devel Ther. 2014 Nov 17;8:2303-10. doi: 10.2147/DDDT.S49778. eCollection 2014.
4
Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.表达表面抗独特型抗体的替代靶细胞用于内化CD22特异性抗体的临床评估。
MAbs. 2015;7(1):66-76. doi: 10.4161/19420862.2014.985519.
5
Novel therapeutic agents in clinical development for systemic lupus erythematosus.正在临床开发用于系统性红斑狼疮的新型治疗药物。
BMC Med. 2013 May 3;11:120. doi: 10.1186/1741-7015-11-120.
6
Biologic therapy for autoimmune diseases: an update.生物疗法治疗自身免疫性疾病：最新进展。
BMC Med. 2013 Apr 4;11:88. doi: 10.1186/1741-7015-11-88.
7
B-cell-targeted therapies in systemic lupus erythematosus.B 细胞靶向治疗系统性红斑狼疮。
Cell Mol Immunol. 2013 Mar;10(2):133-42. doi: 10.1038/cmi.2012.64. Epub 2013 Jan 28.
8
Cellular targeting in autoimmunity.自身免疫中的细胞靶向。
Curr Allergy Asthma Rep. 2012 Dec;12(6):495-510. doi: 10.1007/s11882-012-0307-y.
9
B-cell depletion in the treatment of lupus nephritis.B 细胞耗竭在狼疮肾炎治疗中的应用。
Nat Rev Nephrol. 2012 Sep;8(9):505-14. doi: 10.1038/nrneph.2012.141. Epub 2012 Jul 17.
10
Fine-tuning multiprotein complexes using small molecules.使用小分子精细调节多蛋白复合物。
ACS Chem Biol. 2012 Aug 17;7(8):1311-20. doi: 10.1021/cb300255p. Epub 2012 Jul 23.
本文引用的文献
1
Unanswered questions in evaluating rituximab efficacy: comment on the article by Merrill et al.评估利妥昔单抗疗效中尚未解决的问题：对梅里尔等人文章的评论
Arthritis Rheum. 2010 Aug;62(8):2566. doi: 10.1002/art.27557.
2
The immunological basis of B-cell therapy in systemic lupus erythematosus.B 细胞治疗系统性红斑狼疮的免疫学基础。
Int J Rheum Dis. 2010 Feb 1;13(1):3-11. doi: 10.1111/j.1756-185X.2009.01458.x.
3
B-cell biology and related therapies in systemic lupus erythematosus.系统性红斑狼疮中的 B 细胞生物学及相关治疗。
Rheum Dis Clin North Am. 2010 Feb;36(1):109-30, viii-ix. doi: 10.1016/j.rdc.2009.12.002.
4
Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers.靶向免疫介导的炎症性疾病中的 B 细胞：作用机制的全面综述及生物标志物的鉴定。
Pharmacol Ther. 2010 Mar;125(3):464-75. doi: 10.1016/j.pharmthera.2010.01.001. Epub 2010 Jan 25.
5
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.利妥昔单抗治疗中度至重度活动性系统性红斑狼疮的疗效和安全性：利妥昔单抗治疗系统性红斑狼疮的随机、双盲、II/III期试验
Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233.
6
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.贝利尤单抗治疗活动性系统性红斑狼疮患者的II期随机双盲安慰剂对照剂量范围研究。
Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.
7
A perspective on B-cell-targeting therapy for SLE.系统性红斑狼疮中 B 细胞靶向治疗的观点。
Mod Rheumatol. 2010 Feb;20(1):1-10. doi: 10.1007/s10165-009-0213-x. Epub 2009 Aug 8.
8
Monoclonal antibodies in the treatment of systemic lupus erythematosus.单克隆抗体在系统性红斑狼疮治疗中的应用
Curr Drug Targets. 2009 Jan;10(1):26-37. doi: 10.2174/138945009787122833.
9
Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.奥瑞珠单抗，一种用于治疗炎症性疾病和B细胞恶性肿瘤的抗CD20人源化单克隆抗体。
Curr Opin Investig Drugs. 2008 Nov;9(11):1206-15.
10
Role of B cells in systemic lupus erythematosus and rheumatoid arthritis.B细胞在系统性红斑狼疮和类风湿性关节炎中的作用。
Curr Opin Immunol. 2008 Dec;20(6):639-45. doi: 10.1016/j.coi.2008.08.003. Epub 2008 Sep 18.
Zotero 插件